Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS: ziltivekimab versus placebo for cardiovascular outcomes in ASCVD, CKD, and systemic inflammation
2023-506926-35-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD) and chronic inflammation comparing ziltivekimab with placebo (2 arms). Primary endpoint: 3-point major adverse cardiovascular events. Started Apr 2024; status: completed.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)chronic inflammation
Beyond the preview
Go deeper on 2023-506926-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506926-35-00.